Edge Therapeutics Inc. said it transferred its listing from the Nasdaq Global Select Market to the Nasdaq Capital Market starting March 6.
The Berkeley Heights, N.J.-based biotechnology company's common shares will continue to trade under the symbol EDGE.
The company will also have to regain compliance with Nasdaq's minimum bid price per share requirement, regarding which it received a notice in September 2018.
To regain compliance, the closing bid price per share for the company's common stock should be at least $1.00 for at least 10 consecutive business days.
The company, which has been given additional 180-calendar days to regain compliance, may use a reverse stock split to meet the requirement.